Necrotising Enterocolitis

Overview

Necrotising enterocolitis (NEC) is a devastating gastrointestinal emergency predominantly affecting premature and very low birth weight infants, characterised by intestinal inflammation, bacterial invasion, and potential progression to transmural necrosis and perforation. [1] NEC remains the leading cause of gastrointestinal-related mortality in neonatal intensive care units, with an incidence of 5-12% among very low birth weight infants (less than 1500g) and mortality rates ranging from 20-30%, rising to 50% in surgical cases. [2,3]

The disease represents a multifactorial syndrome resulting from the convergence of intestinal immaturity, abnormal microbial colonisation, inappropriate immune responses, and feeding-related stressors. Despite decades of research and improvements in neonatal care, the incidence of NEC has remained relatively unchanged, with surgical intervention required in approximately 20-40% of affected infants. [4,5]

The clinical significance of NEC extends beyond acute mortality. Survivors face substantial long-term morbidity including neurodevelopmental impairment, growth failure, and in severe cases requiring extensive bowel resection, lifelong intestinal failure requiring parenteral nutrition or intestinal transplantation. Understanding the pathophysiology, early recognition, evidence-based prevention strategies, and optimal management of NEC is crucial for all clinicians caring for premature neonates.

Epidemiology

NEC predominantly affects premature infants, with inverse correlation between gestational age and disease incidence. The condition typically presents between 7-14 days of postnatal age, though timing varies with gestational age at birth. [6]

Risk Factors

Prematurity-Related:

• Gestational age less than 32 weeks (strongest independent risk factor)
• Birth weight less than 1500g (very low birth weight)
• Birth weight less than 1000g (extremely low birth weight)
• Intrauterine growth restriction
• Small for gestational age status

Feeding-Related:

• Formula feeding (4-10× increased risk vs exclusive human milk)
• Rapid feeding advancement (> 20-30 mL/kg/day)
• Hyperosmolar feeds
• Delayed initiation of enteral nutrition

Haemodynamic and Cardiac:

• Patent ductus arteriosus with significant left-to-right shunt
• Congenital heart disease (particularly cyanotic lesions)
• Hypotension requiring inotropic support
• Blood transfusion (transfusion-associated NEC)

Infectious and Inflammatory:

• Chorioamnionitis and maternal infection
• Prolonged rupture of membranes
• Perinatal asphyxia and hypoxic-ischaemic injury
• Systemic antibiotic exposure altering gut microbiome
• Absence of maternal breast milk feeding

Iatrogenic:

• Umbilical artery catheterisation
• Indomethacin or ibuprofen for PDA closure
• Packed red blood cell transfusion
• H2-receptor antagonists or proton pump inhibitors (reduced gastric acidity)

Aetiology and Pathophysiology

NEC is a multifactorial disease arising from the convergence of intestinal immaturity, dysbiosis, and exaggerated inflammatory responses. The pathogenesis involves a complex interplay between host factors and environmental triggers.

Primary Aetiological Factors

Intestinal Immaturity: The premature intestine exhibits reduced epithelial barrier function, diminished mucus production, immature tight junction protein expression, and inadequate secretory IgA production. Immature intestinal motility patterns predispose to bacterial overgrowth and translocation. [8]

Microbial Dysbiosis: Preterm infants demonstrate delayed establishment of commensal bacteria (Bifidobacterium, Lactobacillus) with overgrowth of potentially pathogenic organisms (Enterobacteriaceae, Clostridium species). Dysbiosis is exacerbated by caesarean section delivery, prolonged antibiotic exposure, and lack of human milk feeding. [9] No single causative organism has been consistently identified, though outbreaks involving Klebsiella, Enterobacter, and Clostridium perfringens have been reported.

Abnormal Immune Response: The immature neonatal immune system demonstrates exaggerated pro-inflammatory responses to bacterial products. Toll-like receptor 4 (TLR4) activation by lipopolysaccharide triggers excessive inflammatory cascades, including upregulation of platelet-activating factor (PAF), tumour necrosis factor-α (TNF-α), and interleukin-6 (IL-6), contributing to epithelial injury and necrosis. [10]

Vascular Compromise: Intestinal hypoperfusion from immature vascular autoregulation, patent ductus arteriosus with ductal steal phenomenon, and hypotension may precipitate ischaemic injury. The terminal ileum and proximal colon are most vulnerable due to watershed perfusion zones.

Exam Detail: ### Molecular Pathophysiology

TLR4-Mediated Inflammation: Gram-negative bacterial lipopolysaccharide (LPS) binds TLR4 on intestinal epithelial cells, activating nuclear factor-κB (NF-κB) signalling pathways. This triggers transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8) and chemokines, recruiting neutrophils and macrophages to the intestinal mucosa. In the mature intestine, negative regulatory mechanisms limit TLR4 signalling, but these are deficient in premature infants. [10]

Platelet-Activating Factor (PAF): PAF is a potent pro-inflammatory phospholipid mediator that increases intestinal permeability, promotes bacterial translocation, and causes vasoconstriction and ischaemia. Premature infants have elevated PAF levels and reduced PAF-acetylhydrolase (PAF-AH), the enzyme responsible for PAF degradation. Experimental PAF administration reproduces NEC-like lesions in animal models.

Nitric Oxide Dysregulation: Excessive inducible nitric oxide synthase (iNOS) expression generates high levels of nitric oxide (NO), which combines with superoxide radicals to form peroxynitrite, a highly reactive species causing direct cellular injury, lipid peroxidation, and DNA damage. Enterocyte apoptosis and necrosis result from oxidative stress and mitochondrial dysfunction.

Epithelial Barrier Breakdown: Inflammation disrupts tight junction proteins (occludin, claudins, zonula occludens-1), increasing intestinal permeability. Compromised barrier function allows bacterial translocation into the lamina propria and systemic circulation, perpetuating inflammatory responses and potentially leading to septic shock.

Intestinal Hypoxia: Reduced splanchnic perfusion from cardiovascular instability or ductal steal leads to tissue hypoxia. Hypoxia-inducible factor-1α (HIF-1α) activation initially promotes adaptive responses but prolonged hypoxia triggers apoptosis. Reperfusion injury generates reactive oxygen species, exacerbating tissue damage.

Goblet Cell Dysfunction: Reduced mucin-2 (MUC2) production by immature goblet cells results in thinner mucus layers, facilitating bacterial adherence to epithelial cells. Mucus also contains antimicrobial peptides (defensins, lysozyme) that are deficient in preterm infants.

Paneth Cell Immaturity: Paneth cells in intestinal crypts secrete antimicrobial peptides (α-defensins, lysozyme, phospholipase A2) and growth factors supporting stem cell function. Premature Paneth cells have reduced secretory capacity, diminishing innate immune defences.

Enteric Nervous System Dysfunction: NEC is associated with loss of enteric glial cells and neurons, contributing to dysmotility. Human milk oligosaccharides and specific probiotics have been shown to preserve enteric glia and prevent hypomotility in experimental models. [11]

Formula Feeding as a Major Risk Factor

Exclusive formula feeding increases NEC risk 4-10-fold compared with exclusive human milk feeding. [12] Formula lacks bioactive components present in human milk including secretory IgA, lactoferrin, oligosaccharides, growth factors (epidermal growth factor, transforming growth factor-β), and immune cells. Formula also promotes dysbiotic microbiomes with Enterobacteriaceae predominance versus Bifidobacterium-predominant microbiomes in breastfed infants.

Clinical Presentation

NEC presentations range from subtle feeding intolerance to fulminant intestinal necrosis and septic shock. Clinical deterioration may be insidious or catastrophic. Early recognition requires high clinical suspicion in at-risk infants.

Symptoms and Signs

Early/Non-Specific Features:

• Feeding intolerance (increased gastric residuals, vomiting)
• Abdominal distension (often the first sign)
• Bloody stools (gross or occult haematochezia)
• Apnoea and bradycardia episodes
• Temperature instability (hypothermia or fever)
• Lethargy and reduced activity

Progressive Features:

• Worsening abdominal distension with tenderness
• Abdominal wall oedema and erythema
• Visible bowel loops through abdominal wall
• Absent bowel sounds (ileus)
• Palpable abdominal mass (thickened bowel loop or abscess)

Severe/Late Features (Perforation and Sepsis):

• Cardiovascular collapse and shock
• Severe metabolic acidosis
• Thrombocytopenia and disseminated intravascular coagulation
• Oliguria and acute kidney injury
• Respiratory failure requiring increased ventilatory support

Bell's Staging Criteria (Modified)

Bell's staging criteria, first proposed in 1978 and modified in subsequent years, remain the most widely used classification system despite limitations in diagnostic accuracy and inter-observer variability. [13,14]

Stage I (Suspected NEC):

• IA (Suspected): Temperature instability, apnoea, bradycardia, lethargy; abdominal distension, increased gastric residuals; occult blood in stool

  • "Abdominal X-ray: Normal or non-specific bowel gas pattern, mild ileus"
  • "Management: NPO (nil per os), antibiotics × 48-72 hours if suspicion low"

• IB (Suspected): Above features plus gross bloody stools

  • "Abdominal X-ray: Dilated bowel loops, ileus"
  • "Management: NPO, antibiotics × 7-10 days"

Stage II (Definite NEC):

• IIA (Mildly Ill): Above features plus absent bowel sounds, abdominal tenderness ± palpable mass

  • "Abdominal X-ray: Intestinal pneumatosis ± portal venous gas"
  • "Management: NPO, antibiotics × 10-14 days, close monitoring"

• IIB (Moderately Ill): Above features plus mild acidosis, thrombocytopenia, absent bowel sounds, definite abdominal tenderness ± cellulitis/mass

  • "Abdominal X-ray: Extensive pneumatosis, portal venous gas, possible ascites"
  • "Management: NPO, antibiotics, intensive monitoring, surgical consultation"

Stage III (Advanced NEC):

• IIIA (Severely Ill, Intact Bowel): Above features plus deteriorating vital signs, evidence of shock, marked acidosis, oliguria, disseminated intravascular coagulation, neutropenia

  • "Abdominal X-ray: Prominent intestinal pneumatosis, possible ascites, no free air"
  • "Management: NPO, broad-spectrum antibiotics, intensive support, paracentesis, surgical consultation"

• IIIB (Severely Ill, Perforated Bowel): Above features plus deterioration despite maximal medical therapy

  • "Abdominal X-ray: Pneumoperitoneum (free air)"
  • "Management: Emergency surgery (laparotomy or peritoneal drainage)"

Clinical Pearl: Modified Bell Staging Limitations: Recent statistical analysis of clinical and radiological variables has validated the overall pattern of progression in Bell's staging, though inter-stage boundaries are not always distinct. [13] Some infants progress rapidly from minimal signs to perforation, bypassing intermediate stages. Bell's criteria were developed in the 1970s when affected infants were more mature; contemporary extremely preterm cohorts may present atypically. Alternative definitions focusing on pneumatosis intestinalis as the diagnostic hallmark or incorporating biomarkers are under investigation but not yet standardised. [14]

Differential Diagnosis

NEC shares features with multiple neonatal gastrointestinal and systemic conditions. Distinguishing NEC from mimics is crucial for appropriate management.

Must-Not-Miss Differentials

1. Spontaneous Intestinal Perforation (SIP)

• Distinguishing features: Typically presents earlier (median 7 days vs 14 days for NEC), often in extremely preterm infants less than 26 weeks; focal perforation (usually ileum) without extensive necrosis; associated with indomethacin/ibuprofen and glucocorticoid exposure; pneumoperitoneum without pneumatosis intestinalis
• Implications: Different pathophysiology (localised rather than diffuse inflammation); primary peritoneal drainage often sufficient; better prognosis than surgical NEC

2. Isolated Intestinal Perforation in Term Infants

• Distinguishing features: Occurs in term or near-term infants; may be associated with congenital anomalies (Meckel's diverticulum, intestinal duplication)
• Implications: Requires surgical exploration and treatment of underlying anomaly

3. Malrotation with Midgut Volvulus

• Distinguishing features: Sudden onset bilious vomiting (not gradual feeding intolerance); severe abdominal pain; rapid progression to shock; may occur at any age; upper gastrointestinal contrast study shows duodenal obstruction and abnormal ligament of Treitz location
• Implications: Surgical emergency requiring immediate laparotomy (Ladd's procedure); delay leads to total midgut necrosis and death

4. Congenital Intestinal Atresia

• Distinguishing features: Presents within first 24-48 hours with persistent bilious vomiting; abdominal distension depends on level of obstruction; no feeding history before symptom onset; abdominal X-ray shows double-bubble (duodenal atresia) or dilated loops with air-fluid levels
• Implications: Requires surgical correction; not inflammatory

5. Meconium Ileus/Plug/Peritonitis

• Distinguishing features: Failure to pass meconium within 48 hours; abdominal distension without systemic illness initially; associated with cystic fibrosis (meconium ileus); contrast enema may be diagnostic and therapeutic
• Implications: May require N-acetylcysteine enemas or surgical intervention; check sweat chloride and genetic testing for cystic fibrosis

6. Hirschsprung's Disease

• Distinguishing features: Delayed passage of meconium (> 48 hours in 90%); chronic abdominal distension and constipation; may present with Hirschsprung-associated enterocolitis (fever, abdominal distension, explosive diarrhoea)
• Implications: Requires rectal biopsy for diagnosis; surgical pull-through procedure

7. Cow's Milk Protein Allergy (Allergic Proctocolitis)

• Distinguishing features: Bloody stools without systemic illness; occurs in formula-fed or breastfed infants (maternal dietary protein); infant otherwise well-appearing; eosinophilia on blood film
• Implications: Responds to protein hydrolysate formula or maternal dietary elimination; benign prognosis

8. Neonatal Sepsis (Without NEC)

• Distinguishing features: Systemic signs of infection without prominent gastrointestinal symptoms; abdominal distension may be present due to ileus but without specific radiological NEC features
• Implications: Requires antibiotics but not prolonged bowel rest; can coexist with NEC

9. Gastroenteritis (Viral or Bacterial)

• Distinguishing features: Diarrhoea (usually watery, occasionally bloody); vomiting; typically occurs in older infants; may have contact with infected individuals
• Implications: Usually self-limited; supportive care; rarely causes perforation

10. Cardiac NEC (Associated with Congenital Heart Disease)

• Distinguishing features: Occurs in term or near-term infants with congenital heart disease (especially cyanotic lesions, coarctation, hypoplastic left heart); earlier presentation (median 3 days); associated with cardiovascular instability
• Implications: Higher mortality; often requires cardiac surgical intervention in addition to NEC management

Investigations

Diagnosis of NEC is primarily clinical, supported by radiological findings. No single laboratory test is diagnostic, but multiple parameters aid assessment of severity and guide management.

First-Line Investigations

Abdominal Radiography (Anteroposterior and Lateral/Left Lateral Decubitus): Serial abdominal X-rays (every 6-12 hours initially) are essential for diagnosis and monitoring progression.

Classic Radiological Signs:

1. Pneumatosis Intestinalis: Gas within the bowel wall, appearing as linear/curvilinear lucencies or bubbly cystic patterns; pathognomonic for NEC when present. Pneumatosis may be subtle or extensive; sensitivity varies with gestational age, being less predictive in extremely preterm infants. [15,16]

2. Portal Venous Gas (Hepatic Portal Venous Gas, HPVG): Branching linear lucencies radiating from the liver hilum to periphery, representing gas in portal venous system; indicates severe disease with bacterial translocation; associated with higher surgical intervention rates and mortality.

3. Pneumoperitoneum (Free Intra-Abdominal Air): Gas outside bowel loops indicating intestinal perforation; seen as crescentic lucency beneath anterior abdominal wall on supine films, or as free air above liver/bowel on upright/lateral decubitus views; absolute indication for surgical intervention.

4. Dilated Bowel Loops with Intestinal Ileus: Non-specific early finding; multiple fluid-filled or gas-distended loops with paucity of air distally.

5. Fixed/Persistent Bowel Loop: A single unchanging dilated loop on serial X-rays suggests localised perforation, abscess, or necrotic segment.

6. Bowel Wall Thickening and Separation of Loops: Visible on plain films when severe oedema present; indicates inflammation and possible impending perforation.

7. Asymmetric Bowel Gas Distribution: Absent gas in one region with dilated loops elsewhere may indicate localised necrosis.

8. Gasless Abdomen: Ominous sign suggesting diffuse ileus or massive necrosis; may precede perforation.

Laboratory Investigations:

Full Blood Count:

• Thrombocytopenia (less than 100,000/µL): common, correlates with severity
• Leukocytosis (> 20,000/µL) or leukopenia (less than 5,000/µL): suggests systemic infection
• Neutropenia and left shift: indicates severe sepsis
• Anaemia: may indicate gastrointestinal bleeding or haemolysis

Inflammatory Markers:

• C-reactive protein (CRP): elevated (> 10 mg/L), but non-specific; serial measurements guide treatment duration
• Procalcitonin: may be elevated but not routinely used

Blood Gas Analysis:

• Metabolic acidosis (base deficit > 10 mmol/L, lactate > 4 mmol/L): indicates tissue hypoperfusion and correlates with severity
• Respiratory alkalosis may precede metabolic acidosis

Electrolytes:

• Hyponatraemia: from third-spacing and fluid shifts
• Hyperkalaemia: from tissue necrosis and renal dysfunction
• Hypocalcaemia, hypomagnesaemia: common in critically ill neonates

Coagulation Profile:

• Prolonged PT/APTT, reduced fibrinogen: disseminated intravascular coagulation (DIC)
• Elevated D-dimer: thrombosis or DIC

Renal Function:

• Elevated creatinine and urea: acute kidney injury from hypoperfusion or sepsis

Blood and Other Cultures:

• Blood cultures (aerobic and anaerobic): bacteraemia occurs in 20-30%; common organisms include Staphylococcus epidermidis, Staphylococcus aureus, Escherichia coli, Klebsiella, Enterobacter
• Stool cultures: not routinely helpful; may identify outbreak strains

Stool Analysis:

• Occult or gross blood: common but non-specific
• Faecal calprotectin: elevated, may aid diagnosis but not widely used

Second-Line/Advanced Investigations

Abdominal Ultrasound (Point-of-Care or Formal): Increasingly used adjunct to plain radiography; can detect early changes before radiographic abnormalities. [17]

Sonographic Features of NEC:

• Bowel wall thickening > 2.5-3 mm
• Increased or decreased echogenicity of bowel wall
• Pneumatosis intestinalis (more sensitive than X-ray)
• Portal venous gas with characteristic "sparkling" appearance
• Free fluid in peritoneal cavity (ascites)
• Absent or reversed peristalsis
• Increased colour Doppler flow (hyperaemia) or absent flow (necrosis)
• Complex mass suggesting abscess or necrotic bowel

Advantages of Ultrasound:

• No radiation exposure; can be repeated frequently
• Superior detection of small amounts of free fluid
• Assessment of bowel perfusion and peristalsis
• Detection of portal venous gas and pneumatosis earlier than X-ray
• Can identify complications (abscess, bowel necrosis) not visible on X-ray

Paracentesis (Abdominal Tap): Indicated when ascites present on imaging or clinical examination, to differentiate sterile transudate from infected/perforated bowel contents.

Positive Paracentesis Findings Suggesting Perforation:

• Brown/green discoloured fluid (bile-stained)
• Bacteria on Gram stain
• Elevated white blood cell count
• Positive culture
• Presence of stool (rare)

A positive tap indicating perforation is a strong indication for surgical intervention, even without pneumoperitoneum on imaging.

Serum Biomarkers (Research/Selected Centres): Multiple biomarkers are under investigation but not yet standard practice:

• Intestinal fatty acid-binding protein (I-FABP): elevated with enterocyte injury
• Interleukin-6 (IL-6) and interleukin-8 (IL-8): elevated in severe NEC; IL-6 > 60 pg/mL may predict surgical intervention [18]
• Serum amyloid A: elevated
• Urinary claudin-3: marker of intestinal barrier dysfunction
• Faecal calprotectin: marker of intestinal inflammation

Exam Detail: Radiological Pitfalls and Interpretation Pearls:

Pneumatosis Intestinalis:

• Pneumatosis may be subtle and easily missed; compare with prior films and examine bowel loops carefully
• Linear (subserosal) vs bubbly (submucosal) patterns both diagnostic
• Pneumatosis can occasionally occur in conditions other than NEC (e.g., post-positive pressure ventilation, pneumatosis cystoides intestinalis), but in the appropriate clinical context, pneumatosis is highly specific for NEC
• Absence of pneumatosis does not exclude NEC; up to 20-30% of surgical NEC cases lack pneumatosis on initial imaging [15]

Portal Venous Gas:

• May be transient; repeat imaging if suspicion high
• Branching pattern distinguishes from pneumobilia (which is more central and fewer branches)
• Presence does not mandate surgery if infant clinically stable, but requires intensive monitoring

Pneumoperitoneum:

• Lateral decubitus or upright views more sensitive than supine anteroposterior
• Very small amounts of free air may be physiological after peritoneal drainage or recent line insertion
• In the context of NEC, any pneumoperitoneum is significant

Fixed Loop Sign:

• An unchanging dilated loop on serial X-rays (6-12 hours apart) suggests localised necrosis, perforation, or abscess
• High specificity for requiring surgical intervention

Gold Standard Diagnostic Approach

There is no single gold standard diagnostic test for NEC. Diagnosis requires integration of clinical presentation (Bell's staging), serial radiological findings (especially pneumatosis intestinalis), and laboratory parameters. Pneumatosis intestinalis in the appropriate clinical context (preterm infant with feeding intolerance, abdominal distension, bloody stools) is considered diagnostic of Stage II NEC. However, NEC can exist without pneumatosis, and clinical judgment remains paramount.

Surgical consultation and intraoperative findings (direct visualisation of necrotic bowel) provide definitive confirmation in severe cases, but surgery is reserved for specific indications rather than being a diagnostic procedure.

Management

Management of NEC is stratified by disease severity (Bell staging) and involves aggressive medical therapy with surgical intervention for specific indications. A multidisciplinary approach involving neonatologists, paediatric surgeons, radiologists, and nutritionists is essential.

Initial Stabilisation and Supportive Care

Immediate Actions Upon Suspicion of NEC:

1. Nil Per Os (NPO) and Nasogastric/Orogastric Tube Decompression:

   • Stop all enteral feeds immediately
   • Insert or ensure patency of nasogastric/orogastric tube for continuous or intermittent gastric decompression to reduce bowel distension and risk of perforation
   • Measure and document gastric aspirates

2. Intravenous Fluid Resuscitation:

   • Infants with NEC often have significant third-space fluid losses into bowel wall and peritoneal cavity
   • Initial bolus: 10-20 mL/kg normal saline or Ringer's lactate over 30-60 minutes; repeat as needed guided by clinical response (heart rate, blood pressure, capillary refill, urine output)
   • Maintenance fluids: increase to 150-180 mL/kg/day to account for ongoing losses; adjust based on weight, electrolytes, urine output
   • Monitor for fluid overload; consider furosemide if oliguric despite adequate filling

3. Broad-Spectrum Antibiotics:

   • Cover Gram-positive, Gram-negative, and anaerobic organisms
   • Standard regimen: Ampicillin or vancomycin (if concern for MRSA or high local resistance) + Gentamicin (or other aminoglycoside) + Metronidazole
   • Alternative: Piperacillin-tazobactam + gentamicin or Meropenem (if severely ill or prior antibiotic exposure)
   • Duration: Minimum 10-14 days for medical NEC; may extend if clinical or laboratory parameters remain abnormal
   • Adjust based on blood culture results and local antibiograms

4. Respiratory Support:

   • Many infants deteriorate and require increased respiratory support due to abdominal distension impairing diaphragmatic excursion, sepsis, shock, and metabolic acidosis
   • Increase supplemental oxygen, CPAP, or mechanical ventilation as needed
   • High-frequency oscillatory ventilation or conventional ventilation with permissive hypercapnia may be required

5. Cardiovascular Support:

   • Hypotension is common due to sepsis, third-spacing, and capillary leak
   • After adequate fluid resuscitation, commence inotropes/vasopressors if blood pressure remains low:
     • Dopamine 5-20 µg/kg/min (first-line)
     • Dobutamine 5-20 µg/kg/min (if myocardial dysfunction)
     • Adrenaline/noradrenaline for refractory shock
   • Target mean arterial pressure appropriate for gestational age
   • Consider hydrocortisone for refractory shock (adrenal insufficiency in critical illness)

6. Correction of Metabolic Derangements:

   • Metabolic acidosis: sodium bicarbonate (only if pH less than 7.15 and adequate ventilation); tris-hydroxymethyl aminomethane (THAM) if severe
   • Hypoglycaemia: dextrose bolus and increase glucose infusion rate
   • Hypocalcaemia, hypomagnesaemia: calcium gluconate, magnesium sulphate supplementation
   • Hyperkalaemia: insulin-dextrose, calcium resonium, salbutamol

7. Blood Product Transfusions:

   • Packed red blood cells: if haemoglobin less than 10 g/dL (or less than 12 g/dL if requiring significant respiratory support)
   • Platelets: if less than 50,000/µL (or less than 100,000/µL if evidence of bleeding or planned surgery)
   • Fresh frozen plasma/cryoprecipitate: if DIC with coagulopathy and bleeding

8. Analgesia:

   • NEC causes significant abdominal pain
   • Morphine or fentanyl infusion for analgesia; dose carefully to avoid respiratory depression and hypotension
   • Paracetamol adjunct

9. Monitoring:

   • Continuous cardiorespiratory monitoring (heart rate, respiratory rate, oxygen saturation, blood pressure)
   • Serial clinical examinations (every 2-4 hours) for abdominal distension, tenderness, erythema, perfusion
   • Serial abdominal X-rays (every 6-12 hours initially, then every 12-24 hours)
   • Daily or twice-daily laboratory tests: FBC, CRP, electrolytes, blood gas, coagulation
   • Strict fluid balance monitoring (urine output, gastric aspirates, stool output)

Medical Management by Stage

Stage I NEC (Suspected):

• NPO 48-72 hours minimum
• Antibiotics for 48-72 hours if low suspicion; extend to 7-10 days if Stage IB (gross blood in stool)
• Gastric decompression
• Serial abdominal examinations and X-rays
• Resume feeds cautiously if infant improves and radiographs normalise

Stage II NEC (Definite):

• NPO 10-14 days minimum
• Antibiotics 10-14 days
• Intensive monitoring
• Parenteral nutrition (commenced by day 3-5 to prevent malnutrition)
• Serial abdominal X-rays
• Surgical consultation for close observation
• Resume feeds gradually after clinical and radiological improvement

Stage III NEC (Advanced):

• NPO prolonged duration (14-21 days or until surgical intervention/recovery)
• Broad-spectrum antibiotics ≥14 days (may extend to 21 days)
• Intensive care support (mechanical ventilation, inotropes, blood products)
• Parenteral nutrition
• Surgical intervention (see below)

Surgical Management

Surgical intervention is required in 20-40% of NEC cases. [4,5] The decision to operate balances the risks of ongoing necrosis/perforation against the risks of surgery in critically ill premature infants. Timing of surgery remains controversial, with no universally agreed criteria beyond pneumoperitoneum.

Absolute Indications for Surgery:

1. Pneumoperitoneum (Free Intra-Abdominal Air): Definitive evidence of intestinal perforation; requires urgent surgical intervention
2. Clinical Deterioration Despite Maximal Medical Therapy: Progressive shock, worsening acidosis, multi-organ failure despite aggressive resuscitation and intensive support

Relative Indications for Surgery:

1. Positive Paracentesis: Bile/bacteria/brown fluid on abdominal tap
2. Portal Venous Gas (Persistent or Extensive): Controversial; some centres operate, others observe if infant clinically stable
3. Fixed/Unchanging Bowel Loop on Serial X-rays: Suggests focal perforation or necrosis
4. Palpable Abdominal Mass: May represent abscess or necrotic bowel
5. Severe Thrombocytopenia Refractory to Transfusion: Platelet count less than 50,000/µL despite repeated platelet transfusions suggests ongoing necrosis
6. Progressive Abdominal Wall Erythema and Induration: Indicates peritonitis and possible transmural necrosis
7. Rapidly Worsening Abdominal Distension: May precede perforation

Exam Detail: Surgical Decision-Making: There is significant variation in surgical thresholds between centres. [18] Some surgeons advocate earlier intervention based on clinical and radiological predictors (e.g., extensive portal venous gas, fixed loop sign), while others adopt a conservative approach, operating only for pneumoperitoneum or unequivocal deterioration. Recent studies suggest that earlier surgical intervention (before perforation) does not necessarily improve outcomes and may expose infants to unnecessary surgery. Conversely, delayed surgery in deteriorating infants increases mortality. Optimal timing remains individualised, requiring close collaboration between neonatologists and surgeons. [19]

Biomarkers such as IL-6 > 60 pg/mL and PCT > 5 ng/mL have been proposed as predictors of surgical need but are not yet widely adopted. [18]

Surgical Techniques:

1. Primary Peritoneal Drainage (PPD):

• Insertion of a Penrose drain into the peritoneal cavity (usually right lower quadrant) under local anaesthesia at bedside
• Indications:
  • Extremely unstable infants too sick to tolerate laparotomy
  • Extremely low birth weight infants (less than 1000g) as initial temporising measure
  • Isolated spontaneous intestinal perforation (SIP)
• Advantages: Less invasive, avoids general anaesthesia, can be performed in NICU
• Disadvantages: Does not address underlying necrotic bowel; may miss localised necrosis; some infants require subsequent laparotomy (30-50%)
• Historically viewed as palliative or bridge to laparotomy, but some infants recover with drainage alone

2. Exploratory Laparotomy with Bowel Resection and Stoma Formation:

• Standard surgical approach for NEC requiring operation
• Procedure:
  • Midline laparotomy
  • Thorough exploration of entire bowel from ligament of Treitz to rectum
  • Resection of clearly necrotic, perforated, or non-viable segments
  • Preservation of maximal bowel length (especially ileocaecal valve)
  • Creation of diverting ileostomy/jejunostomy and mucous fistula (or Hartmann's pouch if distal bowel too short for exteriorisation)
  • Closure of abdominal wall (if possible) or temporary silo if abdominal domain insufficient
• Advantages: Allows direct visualisation, resection of necrotic bowel, preservation of viable bowel
• Disadvantages: Requires general anaesthesia, major surgery in critically ill infant, risk of short bowel syndrome if extensive resection
• Stoma reversal: Typically performed 6-12 weeks post-initial surgery, once infant stabilised and growing

3. Primary Anastomosis (Resection Without Stoma):

• Selected cases with limited, clearly demarcated necrosis and well-perfused bowel ends
• Advantages: Avoids stoma and second surgery for reversal
• Disadvantages: Risk of anastomotic leak; should only be performed in stable infants with limited disease

4. Laparoscopy:

• Emerging technique in selected centres for diagnostic laparoscopy ± therapeutic intervention
• May allow identification of necrotic bowel without full laparotomy
• Limited data; not widely adopted

Peritoneal Drainage vs Laparotomy Debate: Two landmark randomised controlled trials (NECSTEPS and NET trial) compared primary peritoneal drainage with laparotomy as initial surgery in extremely low birth weight infants with perforated NEC. [20] Neither trial demonstrated significant differences in mortality or neurodevelopmental outcomes, though both had limitations. Current practice varies by institution, with many centres using PPD as initial intervention in less than 1000g infants or those too unstable for laparotomy, followed by laparotomy if no improvement or ongoing deterioration.

Post-Operative Care:

• Continued intensive support (ventilation, inotropes, antibiotics)
• Prolonged NPO (until bowel function returns and stoma/anastomosis healed; typically 10-21 days post-surgery)
• Gradual reintroduction of feeds (ideally human milk)
• Parenteral nutrition until full enteral feeds achieved
• Management of stoma output (fluid and electrolyte losses)
• Monitoring for complications (anastomotic leak, stricture, abscess, wound infection)

Refeeding After NEC

Resumption of enteral feeding after NEC requires caution to avoid recurrence, which occurs in 2-6% of cases.

Timing to Resume Feeds:

• Stage I NEC: 48-72 hours after resolution of symptoms
• Stage II NEC: 10-14 days, when infant clinically stable, no abdominal distension, stools present, inflammatory markers normalising, abdominal X-rays improving
• Stage III NEC (medical): ≥14 days, often longer
• Post-surgical NEC: 10-21 days post-surgery, once bowel sounds return, stoma functioning

Feed Advancement Strategy:

• Trophic feeds: Start with minimal enteral nutrition (trophic feeding) at 10-20 mL/kg/day for 3-5 days to stimulate gut maturation without significant volume load
• Slow advancement: Increase feeds by 10-20 mL/kg/day if tolerated (based on gastric residuals, abdominal examination, stool output)
• Human milk strongly preferred: Exclusive maternal or donor human milk reduces re-NEC risk; if formula necessary, use extensively hydrolysed or amino acid-based formula initially
• Avoid rapid advancement: Gradual increases reduce re-perfusion injury risk

Monitoring During Refeeding:

• Daily abdominal examinations
• Measure gastric residuals (though management of residuals is controversial; large, discoloured residuals warrant caution)
• Monitor stool output and check for blood
• If any signs of recurrence (abdominal distension, feeding intolerance, bloody stools), stop feeds and reassess

Management of Complications

1. Intestinal Stricture:

• Occurs in 10-35% of NEC survivors, typically 2-8 weeks post-acute illness
• Presents with feeding intolerance, abdominal distension, bilious vomiting
• Diagnosis: Contrast enema or upper GI series showing narrowed segment
• Management: Surgical resection with primary anastomosis

2. Short Bowel Syndrome (SBS):

• Risk when less than 40 cm small bowel remaining (or less than 15 cm if ileocaecal valve preserved)
• Requires prolonged/lifelong parenteral nutrition
• Complications: catheter-related bloodstream infections, liver disease, growth failure
• Management: Specialised intestinal rehabilitation programmes; may require intestinal transplantation in severe cases

3. Neurodevelopmental Impairment:

• NEC survivors (especially surgical NEC) at increased risk of cerebral palsy, cognitive delay, visual/hearing impairment
• Mechanisms: hypotension/hypoperfusion during acute illness, prolonged inflammation, nutritional deficits
• Management: Developmental follow-up, early intervention services

4. Recurrent NEC:

• Occurs in 2-6% after initial episode
• Presents weeks to months later with similar symptoms
• Management: As per initial NEC; may require surgery if previous episode was medical

5. Intra-Abdominal Abscess:

• Persistent fever, leukocytosis, thrombocytopenia despite antibiotics
• Diagnosis: Abdominal ultrasound or CT (rarely performed in neonates due to radiation)
• Management: Surgical drainage or percutaneous drainage if accessible

6. Wound Dehiscence/Infection:

• Post-surgical complication
• Management: Wound care, antibiotics, possible re-suturing or secondary intention healing

Prevention Strategies

Given the high morbidity and mortality of NEC, prevention is paramount. Evidence-based strategies focus on feeding practices, probiotics, and minimising risk factors.

1. Exclusive Human Milk Feeding

Human milk (maternal or donor) is the single most effective intervention to reduce NEC incidence. Multiple meta-analyses demonstrate 3-5-fold reduction in NEC with exclusive human milk vs formula. [12,21]

Mechanisms of Protection:

• Secretory IgA binds pathogens and prevents epithelial adherence
• Lactoferrin has antimicrobial and anti-inflammatory properties
• Human milk oligosaccharides (HMOs) promote Bifidobacterium colonisation, act as decoy receptors preventing pathogen binding, preserve enteric glia, and have direct anti-inflammatory effects [11]
• Epidermal growth factor (EGF) and other growth factors promote intestinal maturation and barrier function
• Maternal immune cells (macrophages, lymphocytes) provide passive immunity

Clinical Recommendations:

• Promote exclusive maternal breast milk; support lactation with pumping education and lactation consultant involvement
• If maternal milk insufficient, use pasteurised donor human milk rather than formula (donor milk retains most protective components except live cells)
• Fortify human milk with human milk-based or bovine-based fortifier once feeds established (≥100 mL/kg/day)
• Delay introduction of formula as long as possible; if unavoidable, use extensively hydrolysed formula

Evidence: A 2020 meta-analysis found exclusive human milk feeding (vs formula) reduced NEC risk with RR 0.51 (95% CI 0.31-0.85). [12] Dose-response effect exists: higher proportion of human milk correlates with lower NEC rates.

2. Probiotic Supplementation

Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits. Multiple systematic reviews and meta-analyses demonstrate probiotics reduce NEC and mortality in preterm infants. [22]

Mechanisms of Action:

• Competitive exclusion of pathogens
• Enhancement of intestinal barrier function
• Modulation of immune responses (reduce TLR4 activation, promote regulatory T-cells)
• Production of short-chain fatty acids (butyrate, propionate) with anti-inflammatory effects
• Reduction of gut pH, creating unfavourable environment for pathogens

Evidence Base:

• Cochrane Review 2020: Probiotics reduce NEC (RR 0.54, 95% CI 0.45-0.65), mortality (RR 0.76, 95% CI 0.65-0.89), and late-onset sepsis. [22]
• Network Meta-Analysis 2021: Multi-strain probiotics containing Bifidobacterium and Lactobacillus most effective (RR for NEC 0.38, 95% CI 0.25-0.58). [23]
• Most trials used combinations of Bifidobacterium (B. bifidum, B. breve, B. infantis, B. longum) and Lactobacillus (L. rhamnosus, L. acidophilus, L. reuteri)

Clinical Implementation:

• Recommended by multiple international guidelines (Canadian Paediatric Society, European Society for Paediatric Gastroenterology Hepatology and Nutrition, British Association of Perinatal Medicine)
• Typical dosing: 1-3 × 10⁹ CFU daily, commenced with first feeds or shortly after, continued until 34-37 weeks postmenstrual age or discharge
• Safety concerns: Rare reports of probiotic sepsis in extremely immunocompromised infants; use pharmaceutical-grade, quality-controlled products
• Barriers to adoption: Lack of FDA-approved probiotic products in some countries (including USA), concerns about strain variability and contamination, cost

Limitations: The 2016 PiPS trial (UK), the largest single RCT of probiotics (Bifidobacterium breve BBG-001), showed no benefit, tempering enthusiasm and highlighting that not all probiotic strains or populations may benefit equally. [24] Optimal strain(s), dosing, and timing remain uncertain.

Current Practice: Many NICUs worldwide routinely administer probiotics to preterm infants less than 32 weeks or less than 1500g. In regions without approved probiotic products, practice varies.

3. Feeding Protocols and Strategies

Gradual, Standardised Feed Advancement:

• Rapid feed increases (> 30 mL/kg/day) increase NEC risk
• Recommended advancement: 15-30 mL/kg/day
• Standardised feeding protocols reduce NEC by decreasing practice variability

Early Introduction of Minimal Enteral Nutrition (Trophic Feeding):

• Small-volume feeds (10-20 mL/kg/day) started within first 2-3 days of life
• Promotes gut maturation without overwhelming immature intestine
• Meta-analyses show early minimal enteral nutrition safe and may reduce NEC

Avoidance of Prolonged Fasting:

• Prolonged NPO delays gut maturation and alters microbiome
• Balance risk of NEC from early feeding vs prolonged fasting; current evidence favours earlier feeding

Human Milk Fortification:

• Preterm infants require additional protein, calcium, phosphate beyond that provided by unfortified human milk
• Fortification typically commenced at 100-150 mL/kg/day
• Human milk-based fortifiers may further reduce NEC vs bovine-based fortifiers (though data limited and cost higher)

4. Avoidance of Modifiable Risk Factors

Judicious Antibiotic Use:

• Prolonged broad-spectrum antibiotics alter gut microbiome, promoting dysbiosis
• Limit antibiotic duration to minimum necessary; avoid empiric antibiotics unless clear infection suspected

Avoid H2-Receptor Antagonists and Proton Pump Inhibitors:

• Gastric acidity provides antimicrobial barrier
• Acid suppression increases NEC and late-onset sepsis risk; use only when strong indication (proven gastroesophageal reflux disease with complications)

Minimise Blood Transfusions:

• Transfusion-associated NEC (TANEC) is well-described, with NEC onset 24-72 hours post-transfusion
• Mechanisms unclear (splanchnic hypoperfusion during transfusion, inflammatory effects of stored blood)
• Strategies: use restrictive transfusion thresholds, withhold feeds during and immediately after transfusion (controversial; evidence conflicting)

Antenatal Corticosteroids:

• Administration of betamethasone or dexamethasone to mothers at risk of preterm delivery accelerates fetal lung maturation and reduces NEC incidence
• Mechanisms: promotes intestinal maturation, upregulates tight junction proteins, enhances barrier function

Delayed Cord Clamping:

• Waiting 30-60 seconds before clamping umbilical cord improves neonatal blood volume, haemodynamic stability
• Associated with reduced NEC in some (but not all) studies

Prognosis

The prognosis of NEC varies significantly based on disease severity, gestational age, presence of complications, and need for surgical intervention.

Mortality

• Medical NEC: 10-20% mortality
• Surgical NEC: 30-50% mortality
• Extremely low birth weight (less than 1000g) surgical NEC: Up to 50-60% mortality

Factors associated with increased mortality:

• Extremely low gestational age (less than 26 weeks) and birth weight (less than 1000g)
• Pneumoperitoneum (perforation)
• Extensive bowel necrosis requiring massive resection
• Multi-organ dysfunction (shock, renal failure, DIC, respiratory failure)
• Presence of congenital heart disease (cardiac NEC)

Long-Term Outcomes in Survivors

Gastrointestinal:

• Intestinal stricture: 10-35%
• Short bowel syndrome: 5-25% of surgical NEC survivors
• Feeding difficulties and prolonged time to achieve full enteral feeds
• Growth failure: up to 50% below 10th percentile for weight at 18-24 months

Neurodevelopmental:

• Increased risk of cerebral palsy, cognitive delay, visual and hearing impairment compared to preterm controls
• Surgical NEC associated with worse neurodevelopmental outcomes than medical NEC
• Mechanisms: hypotension and hypoperfusion during acute illness, prolonged inflammation with cytokine effects on developing brain, nutritional deficits

Other Long-Term Complications:

• Recurrent NEC: 2-6%
• Chronic liver disease (especially if prolonged parenteral nutrition)
• Parenteral nutrition-associated liver disease (PNALD) in SBS
• Psychosocial and economic burden on families

Protective Factors for Better Outcomes:

• Higher gestational age and birth weight
• Early diagnosis and prompt treatment
• Preservation of ileocaecal valve and adequate bowel length at surgery
• Exclusive human milk feeding
• Multidisciplinary intestinal rehabilitation for SBS

Key Guidelines and Recommendations

American Academy of Pediatrics (AAP):

• Endorses exclusive human milk feeding for preterm infants
• Recommends standardised feeding protocols
• Suggests consideration of probiotic use (though acknowledges lack of FDA-approved products)

Canadian Paediatric Society (2021):

• Recommends routine probiotic supplementation for preterm infants less than 1500g or less than 32 weeks

European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN, 2022):

• Conditional recommendation for probiotic use in preterm infants to reduce NEC
• Recommends exclusive human milk feeding

British Association of Perinatal Medicine (BAPM):

• Supports probiotic use with appropriate quality-controlled products

ERN (European Reference Network) Evidence-Based Guideline on Surgical Aspects of NEC (2025):

• Provides recommendations on indications for surgery, peritoneal drainage vs laparotomy, surgical technique, and post-operative management
• Emphasises individualised decision-making and multidisciplinary collaboration [19]

Exam-Focused Content

Common MRCPCH/FRACP/USMLE Exam Questions

1. "What are the classic radiological features of NEC?"

   • Pneumatosis intestinalis, portal venous gas, pneumoperitoneum, dilated bowel loops, fixed loop sign

2. "What is the most important protective factor against NEC in preterm infants?"

   • Exclusive human milk feeding (maternal breast milk or donor milk)

3. "What are the indications for surgical intervention in NEC?"

   • Absolute: pneumoperitoneum, clinical deterioration despite maximal medical therapy
   • Relative: positive paracentesis, portal venous gas, fixed loop, abdominal wall erythema, refractory thrombocytopenia

4. "Describe the modified Bell's staging criteria for NEC."

   • Stage I: Suspected (feeding intolerance, non-specific signs, normal/mild ileus X-ray)
   • Stage II: Definite (pneumatosis intestinalis ± portal venous gas)
   • Stage III: Advanced (perforation or severe deterioration requiring surgery)

5. "What antibiotic regimen would you use for suspected NEC?"

   • Triple therapy covering Gram-positive, Gram-negative, anaerobes: ampicillin + gentamicin + metronidazole OR piperacillin-tazobactam + gentamicin

6. "What is the role of probiotics in NEC prevention?"

   • Meta-analyses show probiotics reduce NEC (RR ~0.5), mortality, and sepsis; multi-strain products most effective; recommended in many international guidelines but not universally adopted

Viva Points

Viva Point: Opening Statement: "Necrotising enterocolitis is a life-threatening inflammatory and ischaemic disorder of the neonatal intestine, predominantly affecting premature infants under 32 weeks gestation, characterised by intestinal necrosis, perforation, and systemic sepsis. It affects 5-12% of very low birth weight infants with mortality rates of 20-30%, rising to 50% in surgical cases."

Key Facts to Mention:

• Incidence: 5-12% of VLBW infants; inversely related to gestational age
• Mortality: 20-30% overall; 35-50% in surgical NEC
• Pathophysiology: Multifactorial—intestinal immaturity + dysbiosis + exaggerated TLR4-mediated inflammation + vascular compromise
• Diagnosis: Clinical (Bell's criteria) + radiological (pneumatosis intestinalis diagnostic) + laboratory
• Pneumatosis intestinalis: Gas within bowel wall; pathognomonic for NEC
• Portal venous gas: Branching lucencies in liver; severe disease marker
• Pneumoperitoneum: Free air; absolute surgical indication
• Management: NPO, NG decompression, fluids, triple antibiotic (amp/gent/met), supportive care; surgery for perforation or deterioration
• Prevention: Exclusive human milk feeding (RR 0.5), probiotics (RR 0.5), standardised feeding protocols, antenatal steroids
• Prognosis: High mortality and morbidity; survivors at risk of SBS, neurodevelopmental impairment, strictures

Common Mistakes That Fail Candidates

❌ Missing red flag features:

• Failing to recognise pneumoperitoneum or clinical deterioration requiring urgent surgical consultation

❌ Inappropriate feeding practices:

• Recommending rapid feed advancement in high-risk preterm infants
• Not prioritising human milk feeding

❌ Incomplete antibiotic coverage:

• Forgetting anaerobic coverage (metronidazole) in NEC antibiotic regimen

❌ Delayed surgical consultation:

• Managing Stage III NEC or perforated bowel medically without surgical involvement

❌ Confusing NEC with spontaneous intestinal perforation (SIP):

• SIP presents earlier, lacks pneumatosis, focal perforation, better prognosis

❌ Not knowing evidence for probiotics:

• Unable to quote meta-analysis data or discuss controversies (e.g., PiPS trial, lack of FDA-approved products)

Model Answers

Q: "A 28-week gestation infant on day 10 of life develops abdominal distension, bloody stools, and increased gastric residuals. How would you manage this infant?"

A: "This preterm infant has features highly suspicious for necrotising enterocolitis. I would approach this systematically:

Immediate Actions:

1. Stop all enteral feeds and insert/confirm nasogastric tube for gastric decompression
2. Assess severity: Full clinical examination—check vital signs, perfusion, abdominal tenderness/erythema, signs of shock
3. Obtain urgent investigations:
   • Abdominal X-ray (AP and lateral/decubitus) looking for pneumatosis intestinalis, portal venous gas, pneumoperitoneum, dilated loops
   • Full blood count, CRP, blood cultures, coagulation, blood gas, lactate, electrolytes
4. Commence broad-spectrum antibiotics covering Gram-positive, Gram-negative, and anaerobes: I would use ampicillin 50 mg/kg IV 12-hourly + gentamicin 4-5 mg/kg IV daily + metronidazole 7.5 mg/kg IV 12-hourly
5. Intravenous fluid resuscitation: 10-20 mL/kg normal saline bolus if signs of shock; then maintenance fluids at 150-180 mL/kg/day
6. Supportive care: Respiratory support if needed; correct acidosis, hypoglycaemia, electrolyte disturbances; blood products if anaemic, thrombocytopenic, or coagulopathic
7. Notify paediatric surgery for close collaboration

Ongoing Management:

• NPO for 10-14 days minimum (if Stage II NEC confirmed)
• Commence parenteral nutrition by day 3-5
• Serial abdominal examinations every 2-4 hours initially
• Repeat abdominal X-rays every 6-12 hours initially, then daily
• Monitor laboratory parameters daily: FBC, CRP, electrolytes, blood gas
• Surgical intervention if pneumoperitoneum, clinical deterioration, or other relative indications develop

Prevention for Future:

• Ensure this infant receives exclusive human milk feeding once refeeding commenced
• Consider probiotic supplementation if unit protocol allows
• Use standardised feeding protocols with gradual advancement (15-20 mL/kg/day)

My management would follow modified Bell's staging criteria and involve close multidisciplinary collaboration with neonatology, surgery, radiology, and nutrition teams."

---

Q: "What evidence supports the use of probiotics in NEC prevention?"

A: "Multiple high-quality systematic reviews and meta-analyses demonstrate probiotics significantly reduce NEC incidence in preterm infants.

Key Evidence:

• Cochrane Review 2020: Analysed 56 RCTs with > 10,000 infants; probiotics reduced NEC (RR 0.54, 95% CI 0.45-0.65), all-cause mortality (RR 0.76, 95% CI 0.65-0.89), and late-onset sepsis.
• Network meta-analysis 2021: Multi-strain probiotics containing Bifidobacterium and Lactobacillus most effective (RR for NEC 0.38, 95% CI 0.25-0.58).
• Most effective strains: Combinations of Bifidobacterium (B. bifidum, B. breve, B. longum) and Lactobacillus (L. rhamnosus GG, L. reuteri).

Mechanism: Probiotics promote healthy gut colonisation, enhance barrier function, modulate immune responses, and competitively exclude pathogens.

Limitations:

• The PiPS trial (2016), the largest single RCT in UK, showed no benefit with B. breve BBG-001, highlighting that not all strains or populations benefit equally.
• Lack of FDA-approved probiotic products in some countries (including USA) limits adoption.
• Rare reports of probiotic sepsis in extremely immunocompromised infants raise safety concerns, though overall safety profile is good with pharmaceutical-grade products.

Current Recommendations:

• Canadian Paediatric Society, ESPGHAN, and BAPM recommend routine probiotic use in preterm less than 1500g or less than 32 weeks.
• Many NICUs worldwide routinely administer probiotics; practice varies in regions without approved products.

In summary, the evidence base is strong, though strain selection, optimal dosing, and universal applicability remain areas of ongoing research."

---

Q: "Describe the radiological features of pneumatosis intestinalis and how you would differentiate it from other causes of bowel gas."

A: "Pneumatosis intestinalis is the pathognomonic radiological finding of NEC, representing gas within the bowel wall itself.

Radiological Appearance:

• Linear pattern: Gas tracks along the subserosal layer, appearing as fine curvilinear lucencies parallel to the bowel wall contour; resembles 'railroad tracks' or 'double-wall sign'
• Bubbly/cystic pattern: Gas in submucosal layer appears as multiple small round lucencies within the bowel wall; resembles 'soap bubbles' or 'Swiss cheese'
• Location: Most commonly ileum and proximal colon (right colon), though can be seen throughout small and large bowel

Differentiating from Normal Bowel Gas:

• Normal intraluminal gas: Appears as central lucency within bowel lumen; changes position with patient movement/bowel peristalsis
• Pneumatosis: Gas is fixed within the bowel wall; does not change with repositioning; creates double contour ('bowel within bowel' appearance)

Other Causes of Pneumatosis (Rare in Neonates):

1. Pneumatosis cystoides intestinalis: Benign, chronic condition; usually older patients; asymptomatic
2. Post-positive pressure ventilation: Mechanical ventilation with high pressures may cause transient pneumatosis without NEC
3. Hydrogen peroxide ingestion: Historical/accidental; not in NICU setting

In the neonatal context with appropriate clinical features (prematurity, feeding intolerance, bloody stools), pneumatosis is highly specific for NEC and warrants immediate action."

---

Q: "When would you choose peritoneal drainage versus laparotomy for surgical NEC, and what are the outcomes of each?"

A: "The choice between primary peritoneal drainage (PPD) and laparotomy remains controversial, with practice varying between institutions and surgeons.

Primary Peritoneal Drainage (PPD):

Indications:

• Extremely unstable infant (severe shock, refractory acidosis, coagulopathy) unable to tolerate general anaesthesia and laparotomy
• Extremely low birth weight (less than 1000g, especially less than 750g) as initial temporising measure
• Suspected isolated spontaneous intestinal perforation (SIP) rather than extensive NEC
• Resource-limited settings where immediate surgical theatre unavailable

Technique:

• Bedside procedure under local anaesthesia
• Penrose drain inserted through small incision (usually right lower quadrant)
• Allows drainage of peritoneal fluid, pus, air
• Can be performed in NICU without transport to operating theatre

Outcomes:

• 40-60% of infants recover with drainage alone (no laparotomy required)
• 30-50% require subsequent laparotomy for ongoing deterioration, inadequate drainage, or persistent disease
• Avoids general anaesthesia risks in critically ill infant
• Does not allow direct visualisation of necrotic bowel; may miss focal necrosis requiring resection
• Similar mortality to laparotomy in NECSTEPS and NET trials

Laparotomy with Bowel Resection:

Indications:

• Haemodynamically stable infant able to tolerate general anaesthesia
• Extensive pneumatosis, portal venous gas, or radiological features suggesting widespread necrosis
• Failed peritoneal drainage (ongoing deterioration, persistent sepsis, inability to wean support)
• Palpable abdominal mass or loculated abscess
• Infant with adequate birth weight (> 1000-1500g) where anaesthetic risk acceptable

Technique:

• Exploratory laparotomy under general anaesthesia in operating theatre
• Systematic examination of entire bowel from ligament of Treitz to rectum
• Resection of clearly necrotic, perforated, or non-viable segments
• Preservation of maximal bowel length (critical to avoid short bowel syndrome)
• Preservation of ileocaecal valve if possible (improves intestinal adaptation and absorption)
• Formation of stoma (ileostomy or jejunostomy) and mucous fistula
• Primary anastomosis rarely performed acutely (high leak risk in setting of inflammation, oedema, instability)

Outcomes:

• Allows definitive treatment with resection of necrotic bowel
• Permits accurate assessment of remaining bowel viability
• Requires second surgery (stoma reversal) 6-12 weeks later once infant stabilised
• Mortality similar to PPD in randomised trials
• Risk of short bowel syndrome if extensive resection (> 50% of small bowel removed)

Evidence from Randomised Trials:

• NECSTEPS trial (2006): 117 infants less than 1500g randomised to PPD vs laparotomy; no significant difference in 90-day mortality (35% PPD vs 36% laparotomy) or neurodevelopmental outcomes at 18-24 months
• NET trial (2008): 310 infants less than 1000g randomised to PPD vs laparotomy; no significant difference in 90-day mortality (34% PPD vs 35% laparotomy)
• Both trials underpowered; some infants randomised to PPD eventually required laparotomy

Current Practice:

• Most centres use PPD as initial intervention in extremely unstable or extremely low birth weight (less than 1000g) infants
• Laparotomy preferred for stable infants > 1000g, those with focal disease amenable to resection, or failed PPD
• Individualised decision-making based on clinical stability, radiological findings, surgical expertise, and institutional protocols
• Close collaboration between neonatology and surgery teams essential for optimal timing and approach

My Approach: In an extremely unstable 700g infant with pneumoperitoneum, I would favour PPD as initial temporising measure, with plan for laparotomy if no improvement within 24-48 hours. In a relatively stable 1200g infant with pneumoperitoneum, I would favour primary laparotomy for definitive treatment."

---

Q: "Discuss the mechanisms by which human milk protects against NEC."

A: "Human milk provides multifactorial protection against NEC through immunological, nutritional, and microbiological mechanisms. Exclusive human milk feeding reduces NEC risk by 3-5-fold compared to formula.

Immunological Protection:

1. Secretory Immunoglobulin A (sIgA):

   • Maternal antibodies coating the intestinal mucosa
   • Binds to pathogens and prevents epithelial cell adherence and translocation
   • Neutralises toxins and virulence factors
   • Does not activate complement, avoiding excessive inflammation

2. Lactoferrin:

   • Iron-binding glycoprotein with antimicrobial properties
   • Sequesters iron, depriving bacteria of essential nutrient
   • Direct bactericidal activity against Gram-negative organisms
   • Anti-inflammatory effects: reduces TNF-α and IL-6 production
   • Promotes growth of beneficial Lactobacillus and Bifidobacterium

3. Lysozyme:

   • Enzyme that cleaves bacterial cell walls, particularly Gram-positive bacteria
   • Synergistic with lactoferrin and immunoglobulins

4. Maternal Immune Cells:

   • Live macrophages and lymphocytes in breast milk (destroyed by pasteurisation)
   • Provide passive immunity and local immune surveillance
   • Produce cytokines and growth factors that modulate neonatal immune responses

Microbiological Protection:

5. Human Milk Oligosaccharides (HMOs):
   • Complex sugars indigestible by human enzymes; third most abundant component of human milk

   • 200 different structures; composition varies between mothers and over lactation

   • Prebiotic effects: Selectively promote growth of Bifidobacterium and Lactobacillus, creating healthy gut microbiome
   • Anti-adhesive (decoy receptor) function: HMO structures mimic epithelial glycans; pathogens bind HMOs instead of intestinal cells, preventing colonisation and invasion
   • Direct anti-inflammatory effects: Reduce TLR4 signalling, decrease NF-κB activation, lower pro-inflammatory cytokine production
   • Preserve enteric glia: Specific HMO structures (2'-fucosyllactose, 6'-sialyllactose) prevent enteric glial cell loss and maintain intestinal motility, reducing bacterial overgrowth and translocation [11]
   • Absent from formula: Cannot be replicated in bovine milk-based formula; some newer formulas now supplemented with synthetic HMOs (2'-FL, LNnT)

Growth Factors and Epithelial Protection:

6. Epidermal Growth Factor (EGF):

   • Promotes intestinal epithelial cell proliferation, migration, and differentiation
   • Enhances mucosal barrier function and accelerates repair of injured epithelium
   • Reduces apoptosis and increases tight junction protein expression

7. Transforming Growth Factor-β (TGF-β):

   • Anti-inflammatory cytokine that downregulates pro-inflammatory responses
   • Promotes oral tolerance and prevents excessive immune activation to commensal bacteria
   • Enhances IgA production

8. Insulin-like Growth Factor (IGF-1 and IGF-2):

   • Promote intestinal growth and maturation
   • Enhance nutrient absorption

Nutritional and Digestive Protection:

9. Bile Salt-Stimulated Lipase (BSSL):

   • Enzyme that aids fat digestion in preterm infants with pancreatic insufficiency
   • Antimicrobial activity against protozoa and enveloped viruses

10. Amylase and Other Digestive Enzymes:

    • Compensate for immature pancreatic function
    • Improve nutrient digestion and absorption, reducing osmotic load on immature intestine

11. Antioxidants:

    • Vitamins A, C, E; glutathione peroxidase; superoxide dismutase
    • Protect against oxidative stress and free radical injury

12. Optimal Osmolality and Composition:

    • Human milk osmolality (~300 mOsm/kg) is isotonic and gentle on immature intestine
    • Formula, especially when concentrated or fortified, can have higher osmolality, causing epithelial injury

Microbiome Shaping:

• Exclusive human milk feeding promotes Bifidobacterium-dominant microbiome (protective, anti-inflammatory)
• Formula feeding promotes Enterobacteriaceae-dominant microbiome (pro-inflammatory, associated with NEC)

Evidence:

• Meta-analysis 2020: Exclusive human milk vs formula feeding RR for NEC 0.51 (95% CI 0.31-0.85); dose-response relationship (higher proportion human milk = lower NEC risk) [12]
• Donor human milk: When maternal milk unavailable, pasteurised donor milk confers similar (though slightly reduced) protection vs formula; pasteurisation destroys live cells but preserves most other protective factors

Clinical Implications:

• Prioritise maternal breast milk expression and feeding
• Use donor milk when maternal milk insufficient
• Delay formula introduction as long as possible
• Educate families on critical importance of human milk for NEC prevention

Human milk is the single most evidence-based, effective intervention to reduce NEC incidence and should be universally promoted and supported in neonatal intensive care."

Human milk is the single most evidence-based, effective intervention to reduce NEC incidence and should be universally promoted and supported in neonatal intensive care."

---

Clinical Scenarios and Case-Based Learning

Scenario 1: Early Recognition

Case: A 26-week, 750g infant on day 12 of life has been advancing feeds well (currently 120 mL/kg/day of maternal breast milk). Overnight, the nurse notes a gastric residual of 15 mL (previous residuals less than 5 mL), mild abdominal distension, and one episode of apnoea. Vital signs are stable. What is your approach?

Answer: This infant has subtle early signs that should raise suspicion for NEC (Stage I):

• Immediate actions: Stop feeds, insert NG tube for decompression, perform focused abdominal examination
• Investigations: Abdominal X-ray (looking for early ileus, bowel distension—pneumatosis unlikely at this early stage), FBC, CRP, blood cultures, blood gas
• Management: If clinical suspicion moderate-high: commence antibiotics (ampicillin + gentamicin + metronidazole), NPO 48-72 hours minimum, serial abdominal examinations and X-rays every 6-12 hours
• Differential: Early NEC vs isolated feeding intolerance vs sepsis without NEC
• Rationale for caution: Extremely low birth weight and early gestational age place this infant at very high risk; single apnoea with increased residuals warrants vigilance even if other signs minimal

Key Learning Point: Early NEC may present with non-specific signs. Low threshold for stopping feeds, imaging, and empiric antibiotics in high-risk infants. Early recognition and intervention may prevent progression to Stage II/III.

---

Scenario 2: Indeterminate Imaging

Case: A 29-week, 1100g infant on day 14 has abdominal distension, bloody stools, and lethargy. Abdominal X-ray shows dilated bowel loops with ileus but no definite pneumatosis. FBC shows thrombocytopenia (80,000/µL), CRP 45 mg/L, lactate 3.2 mmol/L. What is your next step?

Answer: This infant has clinical features highly suspicious for NEC (Bell Stage IB-IIA) but lacks definitive radiological pneumatosis:

• Do not wait for pneumatosis to treat: 20-30% of surgical NEC cases lack pneumatosis on initial imaging; clinical presentation takes precedence
• Immediate management: NPO, NG decompression, IV fluids, broad-spectrum antibiotics (amp/gent/met), supportive care
• Repeat imaging: Abdominal X-rays every 6-12 hours; pneumatosis may develop later, or pneumoperitoneum may appear if perforation occurs
• Consider abdominal ultrasound: May detect early pneumatosis, bowel wall thickening, abnormal perfusion, or free fluid not visible on X-ray
• Surgical consultation: Early involvement even without definitive imaging; close monitoring for deterioration
• Duration of treatment: Treat as Stage II NEC (10-14 days antibiotics, prolonged NPO) given strong clinical suspicion

Key Learning Point: NEC is a clinical diagnosis supported by imaging. Do not withhold treatment awaiting radiological confirmation. Serial imaging and close clinical monitoring are essential.

---

Scenario 3: Surgical Decision-Making

Case: A 30-week, 1300g infant with confirmed Stage IIA NEC (pneumatosis on X-ray, managed medically for 48 hours) develops worsening abdominal distension, abdominal wall erythema, persistent metabolic acidosis (pH 7.15, base deficit -12, lactate 6.5 mmol/L) despite fluid resuscitation and inotropes. Repeat X-ray shows extensive pneumatosis and new portal venous gas but no pneumoperitoneum. Platelets have dropped from 120,000 to 45,000/µL despite transfusion. What is your recommendation?

Answer: This infant has clinical deterioration despite maximal medical therapy with features suggesting extensive bowel necrosis:

• Indications for surgery present:
  • Progressive clinical deterioration (worsening acidosis, shock)
  • Abdominal wall erythema (transmural inflammation/peritonitis)
  • Portal venous gas (severe disease with bacterial translocation)
  • Refractory thrombocytopenia (ongoing tissue necrosis consuming platelets)
• Recommendation: Urgent surgical intervention (laparotomy or peritoneal drainage depending on stability)
• Pre-operative optimisation: Maximise resuscitation, correct coagulopathy (platelets, FFP if needed), ensure adequate ventilation, notify anaesthesia and surgical teams
• Surgical approach: Given weight > 1000g and presence of extensive disease, exploratory laparotomy preferred over peritoneal drainage alone to allow resection of necrotic bowel and assessment of viability
• Consent and parental communication: Discuss guarded prognosis, risk of short bowel syndrome, need for stoma and subsequent reversal surgery

Key Learning Point: Pneumoperitoneum is an absolute indication for surgery, but clinical deterioration despite maximal medical therapy is equally important. Do not delay surgery awaiting perforation in a deteriorating infant—this increases mortality.

---

Scenario 4: Refeeding After NEC

Case: An infant treated for Stage II NEC (pneumatosis on day 10 of life, managed medically) has completed 14 days of antibiotics and NPO. Infant is now clinically well, abdominal examination soft and non-tender, stools present (stoma or per rectum if no stoma), inflammatory markers normalised (CRP less than 5 mg/L), abdominal X-rays showing resolution of pneumatosis and normal bowel gas pattern. When and how would you resume feeds?

Answer:

Timing to Resume Feeds:

• Clinical criteria met: ≥14 days post-diagnosis, clinically stable, resolution of radiological and laboratory abnormalities
• Ready to commence refeeding

Refeeding Protocol:

1. Feed Type: Exclusive maternal breast milk (or donor milk if maternal unavailable); avoid formula initially to minimise re-NEC risk

   • If infant previously on formula and breast milk unavailable, consider extensively hydrolysed formula as alternative

2. Starting Volume: Begin with trophic feeds 10-20 mL/kg/day for 2-3 days

   • Rationale: Prime the gut without significant volume load; promotes enterocyte maturation

3. Advancement: Increase by 10-20 mL/kg/day if tolerated (slower than standard 20-30 mL/kg/day advancement)

   • Monitor for feeding intolerance: gastric residuals, abdominal distension, vomiting, bloody stools

4. Monitoring:

   • Daily abdominal examinations
   • Measure gastric residuals (though management of residuals controversial; large, bile-stained, or bloody residuals warrant caution)
   • Check stools for blood (Haematest/guaiac)
   • If any concerning signs: stop feeds, reassess with examination and imaging

5. Fortification: Once feeds reach 100-150 mL/kg/day and tolerated for several days, commence fortification to meet increased nutritional needs

   • Human milk-based fortifier preferred over bovine-based if available

6. Caution: If signs of feeding intolerance or recurrence develop (re-NEC occurs in 2-6%), stop feeds immediately and treat as new episode

Key Learning Point: Refeeding after NEC requires caution and gradual advancement. Exclusive human milk and slow increases minimise re-NEC risk. Close monitoring with low threshold to stop feeds if intolerance develops.

---

Scenario 5: NEC in a Term Infant with Congenital Heart Disease

Case: A term neonate (38 weeks, 2800g) with hypoplastic left heart syndrome develops abdominal distension and bloody stools on day 4 of life, pre-operatively. What are the specific considerations for cardiac NEC?

Answer:

Cardiac NEC (NEC in Congenital Heart Disease):

• Distinct entity from classic preterm NEC; occurs in term/near-term infants with cardiac anomalies
• Earlier presentation: Median 3-5 days of life (vs 14 days in preterm infants)
• Associated cardiac lesions: Cyanotic congenital heart disease (CCHD), hypoplastic left heart syndrome, coarctation of aorta, total anomalous pulmonary venous return—conditions causing reduced systemic perfusion or diastolic run-off
• Pathophysiology: Mesenteric hypoperfusion from low cardiac output, diastolic steal (e.g., in large PDA or TAPVR), hypoxaemia, and increased systemic vascular resistance; immature gut further compromised by haemodynamic instability
• Higher mortality: 30-50% mortality (higher than preterm NEC); often complicates already critical cardiac condition

Specific Management Considerations:

1. Optimise cardiac output and perfusion:

   • Prostaglandin E₁ infusion if ductal-dependent lesion
   • Inotropic support to maintain adequate systemic perfusion
   • Avoid excessive afterload reduction (may worsen diastolic run-off and coronary perfusion)
   • Maintain oxygen saturation targets appropriate for cardiac lesion (often lower targets in CCHD to balance systemic and pulmonary flow)

2. Standard NEC management: NPO, NG decompression, antibiotics, fluids, supportive care

3. Multidisciplinary collaboration: Cardiology, cardiac surgery, neonatology, paediatric surgery

   • Timing of cardiac surgery: If cardiac operation urgently needed (e.g., stage 1 Norwood for HLHS), balance risk of delaying cardiac surgery vs operating through active NEC
   • Some centres proceed with cardiac surgery despite NEC if haemodynamically necessary, accepting increased operative risk
   • If NEC perforated or requires bowel resection, cardiac surgery usually delayed until NEC stabilised/resolved

4. Feeding strategies post-resolution:

   • Cautious refeeding given high recurrence risk
   • Exclusive breast milk strongly preferred
   • Consider delaying feeds until post-cardiac surgery and haemodynamically stable

Key Learning Point: Cardiac NEC has distinct epidemiology and higher mortality than preterm NEC. Management requires careful balance between cardiac and gastrointestinal priorities. Early involvement of cardiology and cardiac surgery essential.

---

Special Populations and Considerations

NEC in Near-Term and Term Infants:

• Rare (less than 0.1% incidence) but does occur
• Risk factors: Congenital heart disease (most common), intrauterine growth restriction, perinatal asphyxia, polycythaemia, maternal cocaine use, exchange transfusion
• Presentation: Earlier (first week of life), often more fulminant
• Management: As per preterm NEC but investigate underlying predisposing condition (echocardiogram, coagulation studies, toxicology screen)

NEC Totalis (Panintestinal NEC):

• Extensive necrosis involving > 75% of small and large bowel
• Presentation: Rapidly progressive shock, DIC, profound acidosis, often pneumoperitoneum
• Management: Generally considered non-survivable if truly panintestinal; massive bowel resection would leave insufficient bowel for survival (short bowel syndrome incompatible with life)
• Surgical decision: Some surgeons perform exploratory laparotomy to confirm extent; if confirmed panintestinal necrosis, resection futile; palliative care discussion with family
• Rare survivors: Occasional reports of survival with near-total intestinal resection followed by long-term parenteral nutrition and eventual intestinal transplantation

Late-Onset NEC (> 30 days of age):

• Uncommon but described, particularly in extremely preterm infants with prolonged hospitalisations
• Risk factors: Prolonged antibiotics, formula introduction after prolonged human milk feeding, recent stressors (sepsis, anaemia, transfusion)
• Management: As per standard NEC; consider atypical organisms or resistant bacteria given prolonged NICU stay and prior antibiotic exposures

NEC in Infants with Gastroschisis:

• Infants with gastroschisis at higher risk of NEC post-surgical repair
• Proposed mechanisms: Bowel exposure in utero leads to serosal inflammation, dysmotility, and malabsorption; delayed establishment of feeds; altered microbiome
• Prevention strategies: Exclusive human milk, slow feed advancement, vigilance for early signs

---

Long-Term Follow-Up and Multidisciplinary Care

Survivors of NEC, especially surgical NEC, require long-term multidisciplinary follow-up to address complications and optimise outcomes.

Gastrointestinal Follow-Up:

• Growth monitoring: Plot weight, length, head circumference on growth charts; NEC survivors often have growth failure (up to 50% less than 10th percentile at 18-24 months)
• Nutritional support: Dietitian involvement for optimising caloric intake, managing feeding difficulties, fortifying feeds
• Stricture surveillance: Contrast studies 4-8 weeks post-NEC (even if managed medically) if feeding intolerance or obstructive symptoms develop; strictures occur in 10-35% of survivors
• Short bowel syndrome management (if extensive resection):
  • Intestinal rehabilitation team (gastroenterology, surgery, nutrition, nursing, pharmacy)
  • Prolonged parenteral nutrition (PN) with plan for gradual transition to enteral autonomy
  • "Medications: H2 blockers or PPI to reduce gastric hypersecretion; loperamide to slow transit; cholestyramine if bile salt malabsorption; ursodeoxycholic acid for PN-associated liver disease prevention"
  • "Monitoring for PN complications: catheter-related bloodstream infections (CRBSI), liver disease (cholestasis, cirrhosis), metabolic bone disease, micronutrient deficiencies"
  • "Serial Intestinal Failure-Associated Liver Disease (IFALD) monitoring: liver function tests, coagulation, abdominal ultrasound"
  • "Intestinal transplantation: Consider if PN-related complications (irreversible liver failure, loss of venous access, recurrent life-threatening CRBSI) or failure to wean from PN despite maximal medical/surgical management"

Neurodevelopmental Follow-Up:

• Increased risk of cerebral palsy, cognitive delay, speech/language delay, visual and hearing impairment compared to preterm controls without NEC
• Mechanisms: Hypotension and hypoperfusion during acute NEC illness causing cerebral ischaemia; systemic inflammation with cytokine effects on developing brain; nutritional deficiencies during critical period; prolonged hospitalisation and associated stressors
• Follow-up schedule: Standardised neurodevelopmental assessments at 12, 18-24 months corrected age, and school age (as per local high-risk infant follow-up programmes)
• Early intervention: Referral to physiotherapy, occupational therapy, speech therapy if delays detected; developmental support programmes

Surgical Follow-Up:

• Stoma management and reversal: Typically 6-12 weeks post-initial surgery once infant grown, clinically stable, tolerating feeds, and nutritionally optimised
• Wound care: Monitor for incisional hernias, wound breakdown
• Adhesive bowel obstruction: Can occur months-years after abdominal surgery; presents with vomiting, abdominal distension, obstipation; may require further surgery

Psychosocial Support:

• Parental stress and mental health: NEC diagnosis and prolonged NICU stay highly stressful; risk of post-traumatic stress disorder (PTSD), anxiety, depression in parents
• Family support services: Social work, psychology/psychiatry, parent support groups, peer-to-peer mentoring
• Financial counselling: Extended NICU stay and potential long-term medical needs create significant financial burden

Quality of Life:

• Long-term studies show NEC survivors (especially surgical NEC, short bowel syndrome) have reduced quality of life scores compared to preterm controls
• Factors: Feeding difficulties, growth failure, neurodevelopmental impairment, multiple surgeries, prolonged hospitalisations
• Goal of multidisciplinary care: Optimise outcomes and quality of life despite complications

---

References

1. Neu J, Walker WA. Necrotizing enterocolitis. N Engl J Med. 2011;364(3):255-264. doi:10.1056/NEJMra1005408

2. Roberts AG, Younge N, Greenberg RG. Neonatal Necrotizing Enterocolitis: An Update on Pathophysiology, Treatment, and Prevention. Paediatr Drugs. 2024;26(3):259-275. doi:10.1007/s40272-024-00626-w

3. Sha C, Sun W, Wang X, Zhu X, Bass K, Hsieh H, Bialkowska AB. Necrotizing Enterocolitis: What's New and What's Next? Int J Mol Sci. 2025;26(19):9660. doi:10.3390/ijms26199660

4. Robinson JR, Rellinger EJ, Hatch LD, Weitkamp JH, Speck KE, Danko M, Blakely ML. Surgical necrotizing enterocolitis. Semin Perinatol. 2017;41(1):70-79. doi:10.1053/j.semperi.2016.09.020

5. Carr BD, Gadepalli SK. Does Surgical Management Alter Outcome in Necrotizing Enterocolitis? Clin Perinatol. 2019;46(1):89-100. doi:10.1016/j.clp.2018.09.008

6. Duchon J, Barbian ME, Denning PW. Necrotizing Enterocolitis. Clin Perinatol. 2021;48(2):229-250. doi:10.1016/j.clp.2021.03.002

7. Frost BL, Modi BP, Jaksic T, Caplan MS. New Medical and Surgical Insights Into Neonatal Necrotizing Enterocolitis: A Review. JAMA Pediatr. 2017;171(1):83-88. doi:10.1001/jamapediatrics.2016.2708

8. Meister AL, Doheny KK, Travagli RA. Necrotizing enterocolitis: It's not all in the gut. Exp Biol Med (Maywood). 2020;245(2):85-95. doi:10.1177/1535370219891971

9. Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, Mele MC. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms. 2019;7(1):14. doi:10.3390/microorganisms7010014

10. Sodhi CP, Scheese DJ, Tragesser C, et al. Necrotizing enterocolitis: specific human milk oligosaccharides prevent enteric glia loss and hypomotility. Pediatr Res. 2025;98(4):1500-1510. doi:10.1038/s41390-025-04077-y

11. Nolan LS, Parks OB, Good M. A Review of the Immunomodulating Components of Maternal Breast Milk and Protection Against Necrotizing Enterocolitis. Nutrients. 2019;12(1):14. doi:10.3390/nu12010014

12. Altobelli E, Angeletti PM, Verrotti A, Petrocelli R. The Impact of Human Milk on Necrotizing Enterocolitis: A Systematic Review and Meta-Analysis. Nutrients. 2020;12(5):1322. doi:10.3390/nu12051322

13. Juhl SM, Hansen ML, Gormsen M, Skov T, Greisen G. Staging of necrotising enterocolitis by Bell's criteria is supported by a statistical pattern analysis of clinical and radiological variables. Acta Paediatr. 2019;108(5):842-848. doi:10.1111/apa.14469

14. Patel RM, Ferguson J, McElroy SJ, Khashu M, Caplan MS. Defining necrotizing enterocolitis: current difficulties and future opportunities. Pediatr Res. 2020;88(Suppl 1):10-15. doi:10.1038/s41390-020-1074-4

15. Garg PM, Paschal JL, Ansari MAY, et al. Clinical outcomes and gestational age based prediction of pneumatosis intestinalis in preterm infants with necrotizing enterocolitis. J Neonatal Perinatal Med. 2022;15(4):803-812. doi:10.3233/NPM-210971

16. Tong L, Chang YT. Pneumatosis Intestinalis in Necrotizing Enterocolitis. N Engl J Med. 2022;386(11):1070. doi:10.1056/NEJMicm2115830

17. Mishra V, Cuna A, Singh R, Schwartz DM, Chan S, Maheshwari A. Imaging for Diagnosis and Assessment of Necrotizing Enterocolitis. Newborn (Clarksville). 2022;1(1):182-189. doi:10.5005/jp-journals-11002-0002

18. Shang X, Wang H, Liu Y, Yang X, Huang L, Fu H, Xiang L, Xu S. Analysis of early surgical indications and related factors in neonatal necrotizing enterocolitis. Front Pediatr. 2025;13:1571921. doi:10.3389/fped.2025.1571921

19. Hulscher J, Irvine W, Conforti A, et al. European Reference Network for Inherited and Congenital Anomalies Evidence-Based Guideline on Surgical Aspects of Necrotizing Enterocolitis in Premature Neonates. Neonatology. 2025;122(3):376-384. doi:10.1159/000542540

20. Hong CR, Han SM, Jaksic T. Surgical considerations for neonates with necrotizing enterocolitis. Semin Fetal Neonatal Med. 2018;23(6):420-425. doi:10.1016/j.siny.2018.08.007

21. Patel AL, Kim JH. Human milk and necrotizing enterocolitis. Semin Pediatr Surg. 2018;27(1):34-38. doi:10.1053/j.sempedsurg.2017.11.007

22. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2020;10:CD005496. doi:10.1002/14651858.CD005496.pub5

23. Beghetti I, Panizza D, Lenzi J, et al. Probiotics for Preventing Necrotizing Enterocolitis in Preterm Infants: A Network Meta-Analysis. Nutrients. 2021;13(1):192. doi:10.3390/nu13010192

24. Costeloe K, Bowler U, Brocklehurst P, et al. A randomised controlled trial of the probiotic Bifidobacterium breve BBG-001 in preterm babies to prevent sepsis, necrotising enterocolitis and death: the Probiotics in Preterm infantS (PiPS) trial. Health Technol Assess. 2016;20(66):1-194. doi:10.3310/hta20660

---

Disclaimer: This topic is for educational purposes for postgraduate medical examinations. Clinical management should be guided by local protocols, senior colleagues, and current evidence-based guidelines. Individual patient management may vary based on specific circumstances.